These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 2956863

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oral enoximone pharmacokinetics in patients with congestive heart failure.
    Lima JJ, Leier CV, Holtz L, Sterechele J, Shields BJ, MacKichan JJ.
    J Clin Pharmacol; 1987 Sep; 27(9):654-60. PubMed ID: 2960700
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of low dose enoximone for chronic congestive heart failure.
    Jessup M, Ulrich S, Samaha J, Helfer D.
    Am J Cardiol; 1987 Aug 14; 60(5):80C-84C. PubMed ID: 2956875
    [Abstract] [Full Text] [Related]

  • 9. A dose-response study of intravenous enoximone in congestive heart failure.
    Erbel R, Meyer J, Diefenbach C, Delorme G, Bourdarias JP, Vernant P, Lellouche D, Mattioli G, Barbieri A, Installe E.
    Am J Cardiol; 1987 Aug 14; 60(5):31C-36C. PubMed ID: 2956865
    [Abstract] [Full Text] [Related]

  • 10. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
    Uretsky BF, Valdes AM, Reddy PS.
    Circulation; 1986 Mar 14; 73(3 Pt 2):III219-29. PubMed ID: 2935328
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacology of intravenous enoximone: pharmacodynamics and pharmacokinetics in patients with heart failure.
    Smith NA, Kates RE, Lebsack C, Ruder MA, Mead RH, Bekele T, Okerholm RA, Rubin GM, Winkle RA.
    Am Heart J; 1991 Sep 14; 122(3 Pt 1):755-63. PubMed ID: 1831585
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinico-pharmacologic aspects of therapy with enoximone].
    Trenk D, Jähnchen E.
    Z Kardiol; 1994 Sep 14; 83 Suppl 2():7-14. PubMed ID: 8091828
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term treatment with oral enoximone for chronic congestive heart failure: the European experience.
    Treese N, Erbel R, Pilcher J, Choraria S, Rhein S, Dieterich HA, Meyer J.
    Am J Cardiol; 1987 Aug 14; 60(5):85C-90C. PubMed ID: 2956876
    [Abstract] [Full Text] [Related]

  • 17. Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease--relation to plasma concentration.
    Mitrovic V, Petrovic O, Bahavar H, Neuzner J, Dieterich HA, Schlepper M.
    Cardiovasc Drugs Ther; 1991 Aug 14; 5(4):689-95. PubMed ID: 1832289
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT, Janicki JS, Jain MC.
    J Heart Transplant; 1986 Aug 14; 5(2):105-12. PubMed ID: 2956397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.